Lazertinib
Modify Date: 2024-01-06 11:39:50
Lazertinib structure
|
Common Name | Lazertinib | ||
|---|---|---|---|---|
| CAS Number | 1903008-80-9 | Molecular Weight | 554.643 | |
| Density | 1.3±0.1 g/cm3 | Boiling Point | N/A | |
| Molecular Formula | C30H34N8O3 | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of LazertinibLazertinib is a potent, highly mutant-selective, blood-brain barrier permeable, orally available and irreversible third-generation EGFR tyrosine kinase inhibitor, and can be used in the research of non-small cell lung cancer. |
| Name | lazertinib |
|---|---|
| Synonym | More Synonyms |
| Description | Lazertinib is a potent, highly mutant-selective, blood-brain barrier permeable, orally available and irreversible third-generation EGFR tyrosine kinase inhibitor, and can be used in the research of non-small cell lung cancer. |
|---|---|
| Related Catalog | |
| Target |
EGFRT790M |
| In Vitro | Lazertinib (YH25448) is a potent, highly mutant-selective, blood-brain barrier permeable, orally available and irreversible third-generation EGFR tyrosine kinase inhibitor, and can be used in the research of non-small cell lung cancer. Lazertinib targets both T790M mutation and activating EGFR mutations (EGFRm) while sparing wild type[1]. |
| References |
| Density | 1.3±0.1 g/cm3 |
|---|---|
| Molecular Formula | C30H34N8O3 |
| Molecular Weight | 554.643 |
| Exact Mass | 554.275391 |
| LogP | 2.72 |
| Index of Refraction | 1.647 |
| Storage condition | -20℃ |
| 4A2Y23XK11 |
| N-{5-[(4-{4-[(Dimethylamino)methyl]-3-phenyl-1H-pyrazol-1-yl}-2-pyrimidinyl)amino]-4-methoxy-2-(4-morpholinyl)phenyl}acrylamide |
| 2-Propenamide, N-[5-[[4-[4-[(dimethylamino)methyl]-3-phenyl-1H-pyrazol-1-yl]-2-pyrimidinyl]amino]-4-methoxy-2-(4-morpholinyl)phenyl]- |
| lazertinib |